Abstract: TGF-1 is an anti-inflammatory cytokine recognised as a key regulator of immunological homeostasis and inflammatory responses. Furthermore, TGF-1 is important for the regulation of cell growth, differentiation and apoptosis in a wide range of tissues including the intestinal epithelium. Reduced TGF-1 activity is thought to be responsible for the development of autoimmune disorders in several pathological conditions, including inflammatory bowel disease [IBD]. Although the cause of IBD is not yet known, research has shown that a number of factors may be involved including environment, diet and genetics, as well as cytokine exposure. Importantly, IBD is also associated with an increased lifetime risk of developing colorectal cancer, which remains the fourth most common cancer worldwide, representing a significant therapeutic challenge.
INTRODUCTION
TGF-1 is an anti-inflammatory cytokine recognised as a key regulator of immunological homeostasis and inflammatory responses. In addition, TGF-1 is important for the regulation of cell growth, differentiation and apoptosis in a wide range of tissues including the intestinal epithelium [1] .
Reduced TGF-1 activity is thought to be responsible for the development of autoimmune disorders in several pathological conditions, including inflammatory bowel disease [IBD] [2] . IBD is the name of a group of disorders that are characterised by inflammation of the intestine (small and large bowel). IBD affects approximately 1 in 500 people in the UK, and most frequently occurs in people aged 15 to 30. Although the cause of IBD is not yet known, research has shown that a number of factors may be involved including environment, diet and genetics, as well as cytokine exposure [3] . Importantly, IBD is also associated with an increased lifetime risk of developing colorectal cancer, which remains the fourth most common cancer worldwide, representing a significant therapeutic challenge.
The TGF-signalling pathway is commonly disrupted in many cancers, including colorectal cancer, [reviewed in 4] . TGF-proteins are highly conserved, however only TGF-1-3 are expressed in mammals, with tissue-and cell-type specificity in both developing and adult organisms. TGF-1 has a plethora of functions according to the cellular context. In the normal colon, TGF-1 is expressed in the upper region of the crypt, implicating TGF-1 in maintaining colorectal epithelial homeostasis [5, 6] . In normal epithelial cells, TGF-1 signalling elicits a G1-phase cell cycle arrest and direct transcriptional responses of TGF-1 signalling include induction of cyclin-dependent kinase inhibitors, as well as repression of the proto-oncogene, c-MYC. As a secreted protein, TGF-1 may exert autocrine, paracrine or endocrine response, therefore its levels and biological activity must be tightly regulated.
*Address correspondence to this author at the School of Cellular and Molecular Medicine, University of Bristol, Medical Sciences Building, University Walk, Bristol, BS8 1TD, UK; E-mail: ann.C. Williams@bristol.ac.uk Further, highlighting the potential importance of TGF-1 signalling in colorectal carcinogenesis, expression is deregulated in colorectal cancer cells, with increased TGF-1 expression associated with the malignant phenotype [5] . A change in functional response to TGF-1 has been associated with colorectal carcinogenesis: in the early stages of tumorigenesis, colorectal adenomas retain sensitivity to TGF-1 signalling, and the tumour suppressor functions of TGF-1 pose an important barrier to transformation that cells must over-come in order to allow tumour progression. In the later stages of tumour progression, cells develop resistance to the cytostatic effects of TGF-1 (through SMAD4 deletion or mutation of the receptor T RII for example), and increased levels of TGF-1 are associated with colorectal cancer. Hence, tumour-suppressive or potential pro-oncogenic activities predominate depending on cellular context and stage of disease progression. However, despite its altered expression in a number of pathologies, including in the colonic mucosa of patients with IBD, the regulation of TGF-1 expression in normal tissues and in tumorigenesis remains poorly understood.
As functionally implicated in both maintenance of the immune response and tissue homeostasis in the colon, TGF-1 signalling sits at the crossroads between aberrant inflammation and colorectal tumorigenesis. Hence, we review the evidence for cross talk between TGF-1 signalling and pathways important for colorectal tissue homeostasiss, with the emphasis on understanding how deregulation of TGF-1 signalling contributes not only to aberrant inflammatory disease but also to colorectal tumour progression.
THE TGF-SUPERFAMILY
Members of the TGF-superfamily include signalling molecules such as the TGF-s, activins, nodals, bone morphogenic proteins (BMPs), growth and differentiation factor, and Mullerian inhibitory substance. There are many different highly conserved isoforms of TGF-, however only three (TGF-1 to -3) are expressed in mammals, and often distributed with tissue-and cell-type specificity in both developing and adult organisms. The TGF 1 gene is found on chromosome 19q13.1 [7] , while TGF 2 and TGF 3 are on chromosomes 1q41 and 14q24 respectively [8] . Each isoform has different biological functions depending on its spatial and temporal expression, such as deposition of extracellular matrix, inflammation, wound repair and regulation of tissue homeostasis. The isoforms that appear to be most important in the gut are TGF-1 and TGF-3. TGF-3 is expressed by intestinal myofibroblasts in the intestinal mucosa, while TGF-1 is expressed predominantly by epithelial cells [9] .
TGF-1 is a 25kDa disulphide-linked homodimeric protein that was initially identified through its ability to cause anchorageindependent growth and acquisition of a transformed phenotype in fibroblasts [10] . It was shown soon after that TGF-1 is also a potent inhibitor of proliferation of a variety of both normal and neoplastic epithelial cell types [11, 12, 13, 14, 15] . This growth factor is now recognised to play a role in a broad range of cellular processes in mammals, including apoptosis, cell proliferation, and differentiation, epithelial-to-mesenchymal transition (EMT) and immune cell function [reviewed in 16] . These pleiotropic effects are largely dependent on the cell or tissue type and the cellular context, and contribute to a number of physiological processes such as embryogenesis, angiogenesis, tissue homeostasis and wound healing.
TGF-1 GENE EXPRESSION
TGF-1 is ubiquitously expressed, and may elicit autocrine, paracrine or endocrine responses, therefore its levels and biological activity must be tightly regulated since de-regulated activity of TGF-1 has been implicated in a number of conditions including cardiovascular syndromes, chronic inflammation, fibrotic disease and cancer. For example, intestinal levels of TGF-1 are elevated in some inflammatory conditions including in the colonic mucosa of patients with ulcerative colitis and Crohn's disease [2] . Despite its altered expression in a number of pathologies, the regulation of TGF-1 expression in normal tissues and in tumorigenesis remains poorly understood.
Transcriptional Regulation of TGF-1
The TGF 1 gene regulatory region, shown in (Fig. 1) , contains two main promoter regions upstream of the TGF 1 gene that were characterised over 20 years ago [17] . The first promoter, which has been most widely studied, lies -323 to -453 bases upstream of the main transcriptional start site [17] . A second transcriptional start site is found at the 3'-end of the second promoter region, which lies between +1 to +276 in the 5'-UTR of the first exon. Upstream of these promoters are several regulatory regions, including enhancer elements, as well as negative regulatory regions (Fig. 1) .
Multiple putative transcription factor binding sites have been identified in the region upstream of the TGF-1 gene (Fig. 1) . Early reports suggested TGF-1 gene expression is regulated principally by the AP1 transcription factor [18, 19] although other putative transcription factor binding sites include several sites for the SP1 transcription factor [17] , an E2F binding motif/Rb control element [20] , a GC-rich element that binds both EGR1 and WT1 [21] , as well as NF-B consensus sequences [22 144] , and response elements for androgen receptor and glucocorticoid receptor [23, 24] .
Regulation of TGFB1 gene expression by AP1 appears to be particularly important for auto-induction of TGF-1 expression [18] as well as induction in response to phorbol esters, such as 12-Otetradecanoyl phorbol 13-acetate [TPA; 19] , and gamma-radiation [25] . Interestingly, it has been reported that human colon carcinoma cells display constitutive activation of the proximal AP1 site in the human TGFB1 promoter [26] . This study showed that in normal colon epithelial cells, JUN-D and FRA-2 are the major components in the AP1 complex at this site, while in colon carcinoma cells, the AP1 complex contains mostly c-FOS and this is required for increased TGF-1 production and the associated paracrine migratory effects in these cells [26] . An earlier study also showed that retinoic acid receptors (RAR) and retinoid X receptor-alpha (RXR ) can antagonise TPA-induced TGFB1 promoter activity in a human hepatocellular carcinoma cell line through inhibiting binding of JUN and FOS to the TGFB1 gene 5' flanking sequence, and thereby suppressing AP1 transcriptional activity [27] . Most recently, it has been shown that Gep oncogenes (G 12 and G 13) upregulate TGFB1 gene expression through induction of AP1 activity [28] . G 12 and G 13 are heterotrimeric G-proteins that signal downstream of G-protein coupled receptors (GPCR) to stimulate migogenic pathways, predominantly via RHO-GEFs and RHOA [reviewed in 29] . Lee et al. reported that deficiency in G 12/G 13 abolished both basal and TGF-1-induced TGFB1 gene expression and promoter reporter activity in both mouse embryonic fibroblasts and hepatic stellate cells through loss of AP1-dependent regulation of TGFB1 induction. G 12/G 13-mediated regulation of TGFB1 gene expression involves induction of AP1 activity by RHO and RAC GTPases. Further promoter deletion and mutational analyses showed that AP1-induced TGFB1 gene expression involves AP1 binding sites(s) between -323 to -453 upstream of the transcriptional start site, and that the AP1 complex bound to this region contains the JUN-D subunit [28] . The authors infer that G 12 and G 13-mediated induction of TGFB1 gene expression is important for trans-differentiation and cellular transformation of hepatic stellate cells in liver disease, implicating regulation of TGFB1 gene expression by AP1 in tumorigenesis.
In addition to RAR and RXR, several other nuclear hormone pathways have been implicated in the regulation of TGFB1 gene expression. For example, a glucocorticoid responsive element (GRE; 5'-AGAACA) has been identified in the TGFB1 5' flanking region between -981 and -986 [23] , and glucocorticoids such as dexamethasone and budesonide inhibit TGF-1 production through down-regulation of TGFB1 gene expression [30, 31] . Similarly, multiple androgen responsive elements (ARE) have been identified in the human TGFB1 gene regulatory region, to which androgen receptors (AR) bind upon treatment with androgens, and can either positively or negatively regulate TGFB1 gene expression [24] . In normal prostate and prostate cancer cells, TGFB1 expression is inhibited by androgens, however, in metastatic variants of prostate cancer cells, androgens enhance TGFB1 expression, indicating loss of responsiveness at the negative AREs, or gain of responsiveness at the positive AREs [24] . This study indicates that regulation of TGFB1 expression can be altered during tumorigenesis and cancer progression, through use of distinct regulatory elements or by altering the outcome of transcription factor binding at particular sequences.
Finally, various pro-inflammatory cytokines that activate the NF-B signalling pathway, including TNF and IL-1 , have been shown to induce TGF-1 production in a variety of systems [32, 33, 34, 35] , however a direct transcriptional role for NF-B in regulation of TGFB1 gene expression has only recently been reported. The 5' flanking region of the TGFB1 gene contains several B sites, to which the p65 subunit of NF-B has been shown to bind [22] . In a human alveolar epithelial cell line, interaction of the p65 subunit of NF-B with the TGFB1 gene regulatory region mediates upregulation of TGFB1 gene expression induced by the IL-1 inflammatory cytokine, and this is thought to be one mechanism through which IL-1 may contribute to chronic inflammatory lung diseases [22] , although the significance in tumorigenesis is not known. Of interest, recently identified as a regulator of NF-B1 homodimeric complexes [36; NF-B1 function is reviewed in 37], the proto-oncogene BAG-1 has been found to suppress TGFB1 transcription in colorectal tumour derived cells (Skeen et al., manuscript submitted), suggesting that increased expression of BAG-1 in developing adenomas [38] would create an environment permissive for tumour cell growth through suppressing TGF-1 activity effecting both epithelial cell growth and any potential anti-tumour immune response.
Together, these reports show that transcriptional activity of the TGFB1 gene may be both positively and negatively regulated, suggesting that control of TGFB1 gene expression is important in establishing levels of TGF-1 protein available for paracrine or autocrine signalling in both normal and tumour tissue.
ACTIVATION OF TGF-1
The TGF-1 gene product is synthesised as a 390 amino acid precursor peptide which must be proteolytically processed to generate the 112 amino acid mature protein [39] , as shown in (Fig. 2) .
The disulphide-linked homodimeric pro-peptide is secreted as part of a large latent complex, containing latent TGF-1-binding proteins (LTBP) and the latency-associated peptide (LAP), that maintain the pro-TGF-1 molecule in its inactive state. In response to a variety of stimuli, including proteases, low pH, integrin v 6, thrombospondin 1 and reactive oxygen species, the latent complex undergoes a series of activation steps in the extracellular matrix. These include removal of the latency binding proteins, and proteolytic cleavage of the N-terminal pro-peptide domain, to release the active TGF-1 dimer that may then activate downstream signalling pathways. The mature peptide is highly conserved across mammalian species, and this remarkable evolutionary conservation of the mature TGF-1 protein suggests it plays a vital role in normal cell physiology.
TGF-RECEPTORS
There are two major groups of TGF-receptors, the Type I receptor (T RI) and the Type II receptor (T RII), both of which are trans-membrane proteins with serine/threonine kinase activity that are responsible for the cellular responses to TGF-1. The T RII is the primary ligand-binding protein while the T RI is the effector protein that determines signal specificity. Binding of the active TGF-ligand to T RII causes its auto-phosphorylation which recruits T RI and forms the T RII-T RI receptor complex. Constitutive serine/threonine kinase activity of the T RII results in phosphorylation of the regulatory glycine/serine-rich (GS) domain of T RI, and subsequent activation of the serine/threonine kinase domain which initiates cytoplasmic signalling pathways to produce cellular responses.
In addition, a Type III receptor has been identified (T RIII or betaglycan). T RIII is a membrane-anchored proteoglycan that lacks kinase activity but instead has been proposed to act as an accessory receptor to concentrate ligand around the T RII-T RI receptor complex thus enhancing ligand availability [41, 42] . In contrast to this hypothesis that T RIII enhances TGF-signalling, studies in renal epithelial cells suggest that it inhibits TGF-signalling by preventing formation of the T RII-T RI complex [43] . Alternatively, recent studies in breast cancer have suggested that T RIII may inhibit TGF-signalling following release of its soluble ectodomain that acts as a ligand antagonist [44] . This soluble T RIII is able to bind and sequester TGF-, thereby decreasing TGF-signalling and reducing breast cancer invasion and tumourinduced angiogenesis [44] . The function of T RIII in colorectal epithelial cells remains unclear, with reports of both tumour suppressive role and tumour promoting role for T RIII in colorectal disease [45, 46. 47] .
CANONICAL TGF-1 SIGNALLING
Canonical TGF-1 signalling is thought to be largely responsible for the tumour suppressive effects of TGF-1. At first glance, it appears to be a relatively simple, linear pathway, but its signalling is fine-tuned at multiple levels. Importantly, this canonical signalling pathway is commonly de-regulated in colorectal carcinogenesis.
SMAD Proteins
Canonical signalling downstream of the active receptor complex involves SMAD family proteins. The SMAD family comprises 8 SMADs that can be divided in to three functional groups: the receptor-activated SMADs (R-SMADs, SMAD 1/2/3/5/8), the common mediator SMAD (co-SMAD, SMAD4) and inhibitory SMADs (I-SMADs, SMAD6/7). Whereas the co-SMAD, SMAD4, is involved in all SMAD-mediated signal transduction for all TGFsuperfamily members, distinct R-SMADs and I-SMADs act downstream of specific receptors, with SMAD2, SMAD3 and SMAD7 specific for TGF-signalling from the T RII-T RI complex. SMAD proteins are characterised by the presence of globular Mad homology domain(s), MH1 and/or MH2, joined by a linker region. In R-SMAD, the MH1 region is important for cytoplasmic anchoring, as well as nuclear import, DNA binding and regulation of gene transcription, while the MH2 domain functions in SMADreceptor interaction, SMAD oligomerisation, cytoplasmic anchoring and trans-activation [reviewed in 48] .
SMAD proteins are subject to a variety of post-translational modifications, including phosphorylation, ubiquitination and acetylation. Phosphorylation of R-SMADs by the active T RI at their Cterminal SSXS motif is necessary for TGF--SMAD signal transduction. However, phosphorylation elsewhere by other kinases may also regulate SMAD activity. For example, phosphorylation of SMAD2 or SMAD3 in the linker region by ERK, can inhibit SMAD activity [49] . Ubiquitination of SMADs may alter their cellular levels, for example, SMAD2 is specifically ubiquitinated by the E3 ubiquitin ligase, SMAD ubiquitination regulatory factor (SMURF2), which targets SMAD2 for ubiquitin-mediated proteasomal degradation [50] . Alternatively, specific acetylation of SMAD2 and SMAD3 by p300/CBP appears to modulate their nuclear functions, such as DNA-binding and trans-activation [51, 52, 53] .
Signal Transduction by SMAD Proteins
SMAD proteins represent a unique family of signal transduction molecules that can transmit a signal from the cell surface directly to the nucleus where they associate with DNA binding proteins and transcriptional co-activators or co-repressors to regulate target gene expression, summarised in (Fig. 3) . Auto-inhibition of R-SMADs occurs through interaction between the MH1 and MH2 domains, and is disrupted by direct phosphorylation of the SSXS motif in the carboxy-terminal tail by the kinase domain of the active T RI, exposing regions required for oligomerisation with SMAD4. Upon binding of the activated R-SMAD to SMAD4, this heterooligomeric complex translocates to the nucleus where it binds SMAD-binding elements (SBEs) in target gene promoters and regulates gene expression. Well characterised effects of the canonical TGF-1/SMAD signalling pathway on gene expression in epithelial cells include down-regulation of the proto-oncogene MYC [54] , and up-regulation of the cell cycle inhibitors, p21WAF1/Cip1 [55, 56] and p15INK4b [57] , the combined effect of which induces a G1 arrest [reviewed in 16] .
Signal transduction is finely tuned at different levels in the TGF-1-SMAD signalling pathway, including ligand activation, receptor complex formation, R-SMAD activation and translocation, as well as transcription in the nucleus. For example, the SMAD binding protein, SARA (SMAD anchor for receptor activation), which contains binding sites for both SMAD2/3 and T RI, was originally identified through its ability to control localisation of SMADs and its role in presenting R-SMADs to TGF-receptor complex [58] . More recently, SARA has been reported to exhibit preferential interactions with SMAD2 or SMAD3 in a cell typespecific manner [59] . Furthermore, a wide range of proteins, including SP1, c-FOS, E2F4/5, c-JUN and JUN-B, cooperate as SMADbinding partners in the nucleus to direct the SMAD complex towards specific promoters, generating sequence specificity. The SMAD complex in the nucleus can also bind various transcriptional co-activators (e.g. CBP/p300) or co-repressors (TGIF, SKI, SNON), again influencing the choice of SMAD target genes in a cell-type and context-dependent manner.
Another layer of complexity in the regulation of TGF-signal transduction is provided by the inhibitory SMADs (I-SMADs), SMAD6 and SMAD7. SMAD6 is specific for BMP signalling while SMAD7 is an antagonist of TGF-. I-SMADs are characterised by the presence of the conserved MH2 domain at their carboxy-termini, however lack the amino-terminal MH1 domain (Fig.  3) . Interestingly, I-SMADs are induced by TGF-1 signalling, thereby providing an important negative feedback mechanism, and can inhibit TGF-signalling through a variety of mechanisms [reviewed in 60]. Firstly, SMAD7 may compete with R-SMADs for binding to the T RI, thereby blocking phosphorylation of RSMADs and their subsequent association with SMAD4 [61] . Secondly, SMAD7 may recruit protein phosphatases to the TGF-1 receptor complex, such as PP1 and GADD34/PP1c, that can dephosphorylate and therefore inactivate the T RI [62, 63] . Thirdly, in association with the E3 ubiquitin ligases SMURF1/2, SMAD7 can promote ubiquitination and subsequent proteasomal degradation of the T RI [64] . Finally, nuclear SMAD7 can interact with DNA via its MH2 domain, through which it can antagonise TGF-1 signalling by interfering with formation of the functional SMAD•DNA complex [65] .
NON-CANONICAL TGF-1 SIGNALLING
Over recent years, it has become increasingly clear that there is a high degree of cross-talk between TGF--SMAD-mediated signalling and other cellular signalling pathways, but also that TGF-1 can signal via SMAD-independent, non-canonical pathways [reviewed in 66]. Although many of these studies were performed in non-human cell lines, and therefore may represent rather artificial models of human systems, it is thought that these non-canonical signalling pathways may contribute to the potentially pro-oncogenic effects of TGF-1 in human malignancies, for example, through promoting epithelial plasticity, epithelial-to-mesenchymal transition (EMT) and invasiveness, and enhancing cancer cell survival. Some of these non-canonical signalling pathways activated downstream of the TGF--receptor complex (depicted in (Fig. 4) ) are described in the following sections.
TGF-1 and Activation of Protein Phosphatase, PP2A
Interestingly, it has been shown that TGF-1 can induce a G1 cell cycle arrest independently of SMAD signalling in mammary epithelial cells [67] . As shown in (Fig. 4) , this is mediated by the protein phosphatase 2A (PP2A) inhibition of p70S6K kinase. The B subunit of PP2A directly interacts with the active, ligand-bound T RI, and its resultant activation recruits PP2A-A and PP2A-C subunits to form the active phosphatase complex [67] . This PP2A complex is released from the membrane-bound receptor complex to bind and de-phosphorylate its target protein, p70S6K. p70S6K plays an essential role in G1/S transition by translationally upregulating proteins involved in G1/S progression. Therefore, TGF--induced inactivation of p70S6K provides a SMAD-independent mechanism through which TGF-1 can inhibit cellular proliferation.
TGF-1 and Activation of RHO-like GTPase Signalling Pathways
RHOA, RAC and CDC42 are RHO-like GTPases that play roles in cytoskeletal organisation and cell motility [reviewed in 68]. Over recent years, it has been become clear that TGF-1 can activate RHO-like GTPase signalling pathways in both fibroblast [69, 70] and epithelial cell types [71, 72, 73] and this regulation is likely to be important for TGF--induced effects on cell motility and EMT, processes that are particularly relevant to cancer cell invasion [reviewed in 74]. The function of TGF-1-mediated regulation of RHO-like GTPases appears to be twofold: firstly, TGF-1 treatment has been shown to induce re-arrangement of the actin cytoskeleton in various epithelial cell lines, resulting in lamellipodia formation, membrane ruffles, and eventually generation of stress fibres. Independent studies have shown that these rapid changes occur independent of SMAD signalling, and involve RHOA and its downstream effector, p160ROCK, as well as CDC42 [ 71, 75] . The exact mechanism through which TGF-1 activates these RHO-like GTPases and generates rearrangements of the actin cytoskeleton is unclear. Nevertheless, it is likely that TGF-1-induced activation of RHOGTPases involves cross-talk with other signalling pathways such as ERK-MAPK or JNK-SAPK pathways [72] , and at least some of these pathways are SMAD-independent.
Secondly, recent evidence suggests that TGF-1 may also play a role in disassembly of tight junctions in a monolayer of polarised mammary gland epithelial cells through its actions on RHO-like GTPases. This involves direct association of the polarity complex protein, PAR6, with the T RII-T RI complex at tight junctions [73] . Phosphorylation of PAR6 by the ligand-bound T RII-T RI complex causes tight junction dissolution, again contributing to a more motile phenotype [73] .
TGF-1 and Activation of PI3K-AKT Signalling Pathway
The phosphatidylinositol 3-kinase (PI3K)-AKT signalling pathway is involved in multiple cellular processes including cell proliferation, growth, and apoptosis [reviewed in 76]. PI3K is a serine/threonine kinase that converts the membrane bound phosphatidylinositol 4,5-bisphosphate (PIP 2 ) into phosphatidylinositol 3,4,5-triphosphate [77] . Through PDK1 kinase activity, PIP 3 activates the downstream kinase, AKT, which acts as a signalling hub and influences many downstream effectors. Cellular effects of PI3K-AKT signalling include (i) promotion of protein synthesis and cell growth via the mammalian target of rapamycin (mTOR); (ii) suppression of apoptosis via inhibition of Forkhead transcription factors and pro-apoptotic BAD signalling, or activation of NF-B signalling; (iii) induction of cell cycle progression and glucose metabolism via inhibition of GSK3 ; and finally, (iv) modulation of cell cycle arrest, apoptosis and DNA repair through p53 activity [77] . The actions of PI3K are antagonised by the phosphatase PTEN, the genetic or epigenetic inactivation of which results in enhanced PI3K signalling and oncogenic transformation [78, 79] .
The PI3K-AKT signalling pathway is altered in almost 40% of colorectal tumours [80] , and therefore, the observation that TGF-1 rapidly activates PI3K and its downstream effectors in mesenchymal and epithelial cell types [81, 82, 83, 84, 85] presents another pathway through which TGF-1 may achieve its pleiotropic effects in intestinal epithelial cells.
One mechanism for PI3K activation by TGF-1 is through indirect association of the p85 subunit of PI3K with T RII-T RI receptor complex. This is required for PI3K activation upon stimulation by TGF-1 [86] , and, at least in fibroblast cells, this appears to be independent of SMAD2/3 [87] . This may contribute to epithelial cell growth and survival through AKT-dependent regulation of the Forkhead transcription factor, FOXO3A, as has been observed in mammary epithelial cells [85] . Secondly, TGF-1 has been reported Fig. (4) . Overview of non-canonical TGF-1 signalling TGF-1 may activate multiple signalling pathways downstream of the TGF-receptor complex. The mechanisms through which these pathways are activated are discussed in the main text, but may occur independently of SMAD signal transduction molecules. These non-canonical signalling pathways influence a variety of cellular processes including cell motility, cell cycle progression and cell survival, and cell adhesion.
to suppress PTEN expression independently of SMAD signalling, thereby indirectly increasing PI3K activity, resulting in enhanced cell proliferation [82] . The regulation of PI3K-AKT signalling by TGF-1 appears to be particularly important for epithelial cell survival and proliferative responses to TGF-1, however the exact mechanism through which TGF-1 activates PI3K-AKT signalling is not completely understood.
TGF-1 Signalling Mediated by MAPK Pathways

ERK-MAPK
The initial indication that TGF-1 could activate the extracellular signal-regulated kinase (ERK)-MAPK signalling pathway came from an observation in epithelial cells that TGF-1 induces rapid GTP-loading of RAS and downstream activation of ERK [88, 89] , and has subsequently been shown in a variety of cell types [69, 90] . However, the mechanism through which TGF-1 activates RAS-ERK-MAPK signalling has only recently been elucidated, following the observation that, in addition to the serine-threonine transphosphorylation by T RII, T RI can also be phosphorylated on specific tyrosine residues [91] . Lee et al. showed that the adaptor protein, SHCA, is recruited directly to the tyrosine-phosphorylated T RI and its subsequent phosphorylation induces formation of a SHCA-GRB2-SOS complex that is capable of activating RAS and downstream ERK-MAPK signalling [91] . As the ERK-MAPK pathway is a key component in promotion of cellular proliferation and motility in tumorigenesis, it would be logical to suggest that activation of this pathway by TGF-1 could contribute to the prooncogenic effects of TGF-1. Indeed, in pancreatic and breast cancer cells, activation of ERK-MAPK signalling by TGF-1 also induces cytoskeletal changes and increased cell migration [72, 92] , suggesting SMAD-independent regulation of ERK-MAPK signalling by TGF-1 also contributes to EMT and cancer cell invasiveness.
JNK-SAPK and p38-SAPK
JNK (c-JUN N-terminal kinase) and p38 protein kinase are stress-activated protein kinases (SAPK) that mediate signalling in response to cellular stress, inflammatory cytokines or growth factors to elicit a variety of cellular responses, including inflammation, apoptosis, motility, growth or differentiation [93] .
One mechanism through which TGF-1 can activate the p38-or JNK-SAPK pathways has recently been characterised in prostate cancer cells, and involves the E3 ubiquitin ligase protein, TRAF6 (TNF receptor-associated factor 6; 94, 95]. TRAF6 physically associates with the active T RII-T RI receptor complex, independent of T RII or T RI kinase activity, or SMAD binding, resulting in addition of a poly-ubiquitin chain at lysine 63, K63. This activates TRAF6 which then mediates poly-ubiquitination of K63 in TAK1 (TGF--activated kinase). TAK1 is a MAP kinase kinase kinase family member that was originally identified through its ability to positively regulate TGF-1 signalling [96] . Active TAK-1 phosphorylates downstream kinases, MKK3/6 and MKK4, which activate p38 and JNK signalling respectively [97] . Signalling through the TRAF6-TAK1 pathway at the TGF-receptor complex appears to be SMAD-independent [95] , but it is possible that SMAD components are also involved. For example, SMAD7 has been shown to act as a scaffold for TAK-1, MKK3 and p38 [98, 99] .
Activation of JNK by TGF-1 in epithelial cells has been shown to occur in a bi-phasic manner. Initially, a rapid increase in JNK signalling occurs independently of SMADs, while a later peak in JNK activity occurs in cooperation with SMAD pathway signalling [100, 101] . Therefore, it is likely that multiple pathways lead to activation of JNK-and p38-SAPK downstream of TGF-1 depending on a number of factors, including cellular context and signal intensity or duration.
Non-canonical TGF-1 signalling via these SAPK pathways is likely to be involved in a number of responses to TGF-1, including TGF-1-induced apoptosis [98, 99] , as well as TGF-1-induced EMT [81] . For example, TGF-1 signalling via the p38 pathway is required for regulation of TGF-1-induced MMP2/9 expression in mammary epithelial cells [102] , and these pathways are likely to play important roles in TGF-1 functions in both normal tissues and tumorigenesis. However, the cellular contexts in which TGF-1 activates p38 or JNK are poorly understood.
TGF-1 AND SIGNALLING PATHWAYS IMPLICATED IN COLORECTAL TISSUE HOMEOSTASIS 7.1. Wnt/ -catenin Signalling
Wnt signalling regulates a diverse array of cellular events, such as proliferation, differentiation, migration and survival and regulates stem cell renewal in the colonic crypt [103, 104, reviewed in 105] . The canonical Wnt pathway is activated following binding of Wnt ligands to specific receptors of the Frizzled and LDL-receptor families. Following receptor activation, -catenin is stabilised and accumulates in the nucleus, where it binds to the TCF/LEF family of transcription factors to regulate the transcription of target genes [106] . The Wnt pathway is constitutively activated in colon cancer, usually as a result of mutations in the APC gene, the protein product of which forms part of the -catenin destruction complex that controls the ubiquitination and degradation of -catenin. Cross-talk between the TGF-1 and Wnt pathways at both the transcriptional level and via interactions between cytoplasmic components of these pathways, has been studied extensively, particularly in the context of developmental biology [107] . With respect to cancer biology, the Smad and TCF/LEF/ -catenin transcriptional complexes synergistically regulate many common target genes that are over-expressed in colon cancer [108] . One such example, is the regulation of Snail1 and Snail2, which has been shown to be co-regulated by TGF-1 and Wnt [109] and, as the Snail proteins are specifically implicated in EMT, this has important implications for tumour progression in the colon because both the TGF-1 and Wnt pathways are activated.
Hedgehog Signalling
The Hedgehog (Hh) signalling pathway is highly conserved and critically important pathway involved in embryonic patterning and self-renewal pathways in progenitor cells [110] . Signalling is initiated following binding of Hh ligands (Sonic, Indian and Desert) to its membrane receptor PTCH; Smoothened (SMO) is a transmembrane receptor that positively regulates signalling. After receptor activation, SMO is released and enters the primary cilia where it promotes the dissociation of GLI from its complex with Suppressor of Fused (SUFU). Following nuclear translocation, the transcription of the glioma-associated (Gli) family of transcription factors is activated and this, in turn, regulates target gene expression. The Hh pathway has been shown to be activated, via PTCH mutation or elevate Gli expression, in a variety of cancers, including those of the gastrointestinal tract and also shown to be important in the tumour microenvironment [111] . Recent data has shown that TGFcan activate the Hh pathway independently of Hh receptor activation [112] . Specifically, TGF-1 induces the expression of Gli2 in a Smad3-dependent manner and, this, in turn, leads to the regulation of target gene expression, including the upregulation of Gli1 [113] . Intriguingly, Gli2 transcription may also be controlled by TCF/LEF/ -catenin, indicating that this pathway is also regulated by Wnt [114] . Conversely, Hh signalling can also activate the TGFpathway, as Yoo et al. [115] showed that Shh promotes motility and invasiveness of gastric cancer cells through TGF--mediated activation of the ALK5-Smad 3 pathway.
Notch Signalling
The Notch signalling pathway has been shown to regulate the balance between proliferation, differentiation and apoptosis in a variety of cell types and is, therefore, critical in determining cell fate. The pathway is activated when the Notch receptor (Notch 1-4) is activated following binding of Notch ligands (Jagged 1 and 2; Delta-like 1, 3 and 4) in a process that requires cell-cell contact [116] . Following ligand binding, Notch is cleaved by -secretase to release the Notch intracellular domain (NICD), which then translocates to the nucleus and complexes with the CSL family of transcription factors, resulting in the transcription of target genes, such as Hey , Hes and Herp. In the colon, Notch 1 and Jagged 1 are expressed in the proliferative compartment of the crypt, where they are thought to inhibit the expression of KLF4; loss of Notch activity in the upper compartments of the crypt results in KLF4 expression in the differentiated layers [117] . Interestingly, KLF4 expression is reduced in colon cancers [118] and haploinsufficiency of KLF4 induces adenoma formation in the ApcMin/+ mouse [119] . TGF-1 can upregulate the Jagged and Hes ligands in a number of cell types and TGF-and Notch co-regulate many common target genes [107] . Recently, it has been shown that inhibition of Notch signalling can attenuate both basal and TGF-1-induced TGF-signalling in clear cell renal cell carcinoma [120] .
CONTEXT-DEPENDENT FUNCTIONS OF TGF-1 8.1. TGF-and Immune Regulation
In order to delineate roles for TGF-1 in development, Shull and colleagues generated Tgfb1 null mice [121] . The Tgfb1-/-genotype produced a significant degree of intrauterine lethality, however the pups that survived to birth developed normally for the first 10-14 days before rapid loss of weight by day 21 and death between 3-4 weeks of age. Histopathological examination revealed tissue necrosis and massive inflammation in multiple organs, demonstrating a prominent role for TGF-1 in immune cell regulation [121] . Smad3 has been shown to play a key role in TGF--dependent antiinflammatory and immunosuppressive activities in the gut, as Smad3 mutation in mice results in premature death due to defects in their mucosal immunity; Smad3 mutant mice invariably developed a variety of immune-related conditions, including gastritis, colitis and chronic infection with abscess formation adjacent to mucosal surfaces [122] . Additionally, mice expressing dominant-negative T RII under the control of a T-cell-specific promoter have been shown to develop marked-severe inflammatory bowel disease [123] .
Since the early studies using transgenic mice implicating a major role for TGF-1 in immunity and inflammation, much effort has been focused on elucidating the precise effects of TGF-on T-cell function and it is now known that TGF-modulates processes involved in T cell development, tolerance, homeostasis and differentiation [124] . TGF-can have both immunosuppressive and proinflammatory effects, depending on the cellular context. For example, TGF-1 inhibits T-cell proliferation and, by down-regulating the expression of specific transcription factors (eg. T-bet, GATA-3, STAT4), blocks the differentiation of Th1 and Th2 cells [124] . Additionally, TGF-stimulates the induction of regulatory T-cells (Treg) by promoting the transcription of Foxp3 in naive T-cells in a Smad3-dependent manner, although the exact mechanism Foxp3 induction has yet to be determined [125] . These immune suppressive effects of TGF-are important for peripheral tolerance, particularly in the gastrointestinal tract, where immunosuppression by TGF-1 controls intestinal inflammation in response to environmental insults, such as food antigens present in the gut contents. By contrast, in the presence of IL-6, TGF-is responsible for the commitment of naive T-cells to a Th17 lineage [126] and it is now known that Th17 cells (via the production of IL-17) are responsible for the development of chronic autoimmune and inflammatory states. These data highlight the very contextual nature of the role of TGF-in regulating immune responses, with the ligand eliciting either immunosuppressive or pro-inflammatory responses dependent upon the presence or absence of IL-6, for example.
TGF-1 and Inflammatory Disorders of the Colon
The mucosal immune system of the gut plays a central role in the pathogenesis of IBD. Chronic mucosal inflammation is caused by hyper-activation of effector immune cells which produce high levels of pro-inflammatory cytokines, including TNF and IL-1. Tissue homeostasis and immune tolerance are critical in the normal colonic epithelium and are achieved, in part, through a balance of pro-and anti-inflammatory mediators. TGF-1 is an important antiinflammatory cytokine in intestinal tissue, not only for maintenance of tissue homeostasis but for preventing destruction of the intestinal mucosa under physiologically relevant conditions. Suppression of TGF-1 signalling is considered important for the generation of autoimmune disease; decreased activity of suppressive cytokines has been implicated in deregulation of the immune response, a process underlying inflammatory bowel disease [IBD] [127] .
The eitiology of IBD, the two major forms of which are Crohns disease [CD] and Ulcerative Colitis [UC], remains unknown although there is evidence to suggest that chronic intestinal inflammation associated with IBD may be caused by an excessive immune response to mucosal antigens. Interestingly, intestinal lymphocytes have been shown to produce TGF-1 at sites of antigen exposure (at the villi rather than in the less accessible crypt structures) implicating an important role for TGF-1 in maintaining limiting the inflammatory response to antigenic stimuli. Furthermore, depletion of TGF-1 has been shown to enhance the immune response leading to damage of the intestinal mucosa [reviewed in 3] .
Despite the observation that systemically TGF-1 is associated with immune suppression, it is thought that increased production of TGF-1 by cells in the underlying lamina propria may have local pro-inflammatory effects, promoting progression of the disease [128] . Further, increased TGF-1 has been reported both in UC and CD tissue, although it is possible that this occurs as a result of the response to mucosal damage (as a consequence of tissue regeneration and/or fibrosis for example) as opposed to being an event associated with the initial phase of IBD [reviewed in 127]. Increased expression of SMAD7 in IBD mucosal cells as well as in the purified infiltrating mucosal T cells suggests that increased SMAD7 contributes to defective TGF-1 signalling in the inflamed tissue, making cells unresponsive to inhibitory TGF-1 signalling [129] . Further, patients with active IBD also show reduced levels in phosphorylated SMAD 3 compared to control subjects, evidence that supports the idea that there is a reduced response to TGF-1 despite the fact that it is highly expressed in the inflamed tissue [128] . Taken together these studies suggests that dysregulation of TGF-1 signalling is important in the pathogenesis of IBD.
Importantly, chronic inflammation has been linked to the development of a variety of human cancers, including colorectal carcinoma. Tumorigenesis in the GI tract is closely associated with chronic inflammation, and abnormal cellular processes such as oxidative stress, gene mutations, epigenetic changes and inflammatory cytokines are shared with the carcinogenic process [refer to 130]. To better understand how deregulated TGF-1 signalling can contribute to colorectal carcinogenesis, it is important first to understand the role of TGF-1 in colorectal epithelial cells
TGF-1 IN EPITHELIAL CELLS
In epithelial cells, canonical TGF-1 signalling plays a particularly important role in controlling cell cycle progression by inducing a G1 phase growth arrest through regulation of a well characterised program of target genes as mentioned earlier. TGF-1 is also particularly important in promoting differentiation of epithelial cells, particularly in the intestinal epithelium [131, 132] , although the mechanism through which this occurs is less well characterised than TGF-1-induced growth arrest.
In addition to its effects on cell proliferation and differentiation, TGF-1 is also involved in induction of apoptosis in a cell typeand context-dependent manner [reviewed in 16] . These responses have largely been characterised in prostate epithelial cell lines and hepatocytes, as well as non-epithelial cell types, namely lymphocytes. The mechanisms through which TGF-1 induces apoptosis are not yet fully understood, but appear to engage both SMADdependent [60, 98, 133, 134] and SMAD-independent pathways [95, 135, 136] in different cell types. TGF-1-induced apoptosis is also likely to involve a high degree of cross-talk with other signalling pathways, such as p38-and JNK-SAPK pathways.
TGF--induced Epithelial-to-mesenchymal Transition
Epithelial-to-mesenchymal transition (EMT) is an important physiological process in embryogenesis and in adult tissues morphogenesis. During EMT, a coordinated temporal sequence of events occurs as epithelial cells acquire phenotypic characteristics of fibroblastic cells. This process involves disassembly of cell-cell junctions, re-organisation of the actin cytoskeleton, loss of apicalbasolateral polarity and re-modelling of cell-matrix adhesions [reviewed in 16]. EMT is also an important process in cancer progression, particularly in cancer invasion and metastasis, however oncogenic EMT also requires additional abnormalities such as anoikis resistance and autonomous growth potential.
Seminal experiments, largely performed in normal mouse mammary epithelial cells (NMuMG cells) have shown that TGF-1 plays an essential role in EMT in vitro [137, 138] . However, studies have also shown that TGF--induced EMT is an important process in vivo, both during development, and in carcinogenesis [reviewed in 139]. TGF--induced EMT may be SMAD-dependent [140] , but is likely to also involve cross talk with parallel signalling pathways, most notably RAS signalling, which has been shown to synergise with TGF-1 to induce EMT [141, 142, 143] . Nevertheless, SMAD-independent signalling is likely to contribute to TGF-1-induced EMT, and the non-canonical signalling pathways, including ERK-MAPK, PI3K-AKT, and RHO-GTPase pathways have all been implicated. Through these SMAD-dependent or -independent pathways, TGF-1 may promote morphological changes characteristic of EMT and associated with increased motility. In a cellular context of other growth and survival abnormalities in cancer cells, induction of EMT by TGF-1 may be particularly important for invasion and metastasis.
TGF-1 in the Stroma
TGF-1 is known to induce proliferation and motility of fibroblasts, but may exert other paracrine effects in the stroma. In normal tissues, TGF-1 stimulates assembly and remodelling of extracellular matrix (ECM) by (i) increasing production of ECM proteins such as collagen and fibronectin; (ii) decreasing the production of enzymes that degrade the ECM, including collagenase and heparinase; and (iii) increasing the production of these protease inhibitors, for example plasminogen activator inhibitor-1 (PAI-1) and tissue inhibitor of metalloproteinase [TIMP; reviewed in 144]. Therefore, TGF-1 can influence cell-matrix adhesion and wound healing through its role in ECM remodelling, chemotaxis and proliferation of fibroblasts.
Through its effects on the stroma, TGF-1 may also play a role in disease, such as fibrosis and neoplasia. TGF-1 induces expression of fibrillar collagens and inhibits degradation of ECM by down-regulating expression of matrix metalloproteinase-1 (MMP-1), together leading to accumulation of ECM and promotion of fibrosis, particularly in the skin, liver, kidney, eye, lung and cardiovascular system [145] . Conversely, during tumorigenesis, TGF-1 frequently enables increased motility of cancer cells by increasing the expression of proteolytic matrix-degrading enzymes [144] , facilitating tumour invasion and metastasis.
TGF-1 and Angiogenesis
Further investigation into the pre-natal lethality in Tgfb1-/-embryos revealed a role for TGF-1 in vasculogenesis and haematopoiesis, and maintenance of vessel wall integrity [146] , implicating TGF-1 in proper development of the cardiovascular system. In adult tissues, TGF-1 may act in a bi-functional manner to affect angiogenesis, according to different cell surface receptors, and according to levels of TGF-1 ligand. For example, low levels of TGF-1 may contribute to the angiogenic switch by up-regulating angiogenic factors and proteinases, while high TGF-1 concentrations inhibit angiogenesis [reviewed in 147] . TGF-1 may block angiogenesis by signalling through the T RII-T RI complex via SMAD2/3 to inhibit proliferation, tube formation and migration of endothelial cells [148] ; similarly, TGF-1 can inhibit growth of vascular smooth muscle cells, and induce differentiation to a contractile phenotype [149] .
Interestingly, TGF-1 has been shown promote angiogenesis in several tumour types [150, 151, 152, 153, 154, 155] , although this appears to largely be through indirect mechanisms. As tumours outgrow their existing blood supply, they must recruit endothelial cells to generate new blood vessels and form a microcirculation, supplying the ever increasing demands of the tumour. TGF-1 may augment tumour angiogenesis through induction of vascular endothelial growth factor (VEGF) from both fibroblastic and epithelial cells to stimulate proliferation and migration of endothelial cells [156] . In addition, in tumour cells, TGF-1 can also induce production of matrix metalloproteinases, specifically MMP-2 and MMP-9 [157, 158, 159, 160] . MMPs recruit endothelial cells and pericytes, and contribute to remodelling of ECM, thus creating routes through the surrounding tumour matrix for growth of new vessels. Therefore, TGF-1 may act as a potent activator of tumour progression through its effects on tumour angiogenesis to allow tumour growth, while the new vessels also provide routes for dissemination and metastasis.
TGF-1 IN CANCER 10.1. TGF-1 and the Tumour Microenvironment
As mentioned in prior sections, TGF-1 is an important cytokine in the development and progression of tumours of epithelial origin, and its role in tumorigenesis appears to be two-fold (see Fig.  5 ), functioning as both a tumour suppressor and a promoter. Not solely explained by switch from SMAD dependent to SMAD independent signalling, TGFB1 exerts complex effects on both immune and stromal cells within the tumour microenvironment, recently elegantly reviewed by Moses and colleagues [161] .
In the early stages of colorectal tumour development, TGF-1 acts as a tumour suppressor through its effects on cell cycle arrest and apoptosis. During tumour progression, however, tumour cells develop resistance to the cytostatic effects of TGF-1 and in later stages of malignancy, TGF-1 may act as a pro-oncogenic factor. Tumour-suppressive or pro-oncogenic activities predominate depending on cellular context, and stage of disease progression. TGF-1 may participate in tumour cell autonomous signalling, or paracrine signalling to the tumour microenvironment, such as immune cells, endothelial cells and stromal cells.
Disruption of Canonical TGF-1 Signalling in Colorectal Tumorigenesis
De-regulation of the canonical TGF-1 signalling pathway is associated with several pathological states such as cancer, autoimmune disease and fibrosis. In cancer, genetic alterations in the canonical TGF-1 signalling pathway correlate with loss of sensitivity to the growth inhibitory effects of TGF-1, an event that is likely to be important in the switch of TGF-1 from tumour suppressor to tumour promoter [reviewed in 4].
The TGFBR2 gene contains microsatellite sequences comprising 10bp poly-adenine repeats called the big adenine tract in receptor Type II (BAT-RII). The BAT-RII is highly susceptible to replication errors, especially in cancers driven by microstaellite instability (MSI) with mismatch repair (MMR) gene inactivation. Nonsense mutations in TGFBR2 are found in at least 80% of MSI colorectal cancers [162] , but their overall incidence in sporadic colorectal carcinogenesis is 30% [163] . Genetic alterations in TGFBR2 lead to production of a truncated receptor incapable of signal transduction, but interestingly, these patients show improved 5-year survival [164] . This suggests that TGF-1 signalling downstream of the receptor complex, likely involving non-canonical TGF-1 signalling, is indeed important for colorectal cancer progression.
In addition to inactivation of the T RII, genetic alteration of the SMAD4 gene on chromosome 18q21.1 is a frequent event in human cancers [165] . The SMAD4 gene undergoes mutation or targeted deletion in 16-24% of colorectal cancer cases [166, 167] with chromosome 18q representing a region that often undergoes LOH in colon adenocarcinomas. Loss or inactivation of SMAD4 appears to be a relatively late step in cancer progression with the majority of SMAD4 alterations occurring in invasive colorectal carcinomas but not adenomas [165] . SMAD4 is therefore considered to be a tumour suppressor gene. The SMAD2 gene, also present on chromosome 18q, is lost in a proportion of in colorectal cancers [168] . Alternatively, SMAD3 mutations are rare [169, 170] and their pathogenic role remains unclear.
Given its role in tumour suppression, it is somewhat surprising that TGF-1 levels are frequently up-regulated in a number of cancers, including colon cancer, and its high expression is associated with disease progression and metastasis [167, 171, 172, 173] . Upregulation of TGF-1 occurs most commonly in advanced cancers, after the tumour has acquired resistance to the growth inhibitory effects of TGF-1 [174] ; however the mechanisms through which this occurs are not clear. In other cancer types, high TGF-1 is thought to contribute to cancer progression and invasion, although whether TGF-1 assumes pro-oncogenic activities in colorectal cancer cells is yet to be established [175] .
THERAPEUTIC POTENTIAL OF THE TGF-PATH-WAY
As already discussed, TGF-plays a major role in embryonic development and in the maintenance of adult tissue homeostasis by regulating a diverse array of cellular processes, such as proliferation, differentiation, epithelial to mesenchymal transition and apoptosis. It is perhaps not surprising, therefore, that aberrant TGFsignalling has been associated with a diverse range of disease pathologies, including fibrotic disorders of the heart, lung and liver, cardiovascular disease and cancer [176, 177] . Consequently, a number of strategies to target the TGF-signalling pathway therapeutically are being developed, including neutralising antibodies, antisense oligonucleotides, soluble receptors and small molecule inhibitors of the T RI kinase and clinical studies are ongoing to evaluate their safety and efficacy [177] .
There is some evidence to indicate that interfering with the TGF-signalling pathway may be beneficial in the treatment of malignant and inflammatory diseases of the colon. For example, ectopic expression of soluble T RII inhibited the growth of tumours formed by HCT116 colon carcinoma cells in nude mice [178] and LY2109761, a dual T RI and T RII kinase inhibitor, decreases liver metastasis and increases survival in an experimental model of colorectal cancer metastasis [179] . Further, the antisense TGF-2 oligodeoxynucleotide, Trabedersen (AP 12009), which has shown very promising results in trials of patients with high-grade glioma, is currently being evaluated in trials for the treatment of patients with metastatic colorectal carcinoma [180] . With regards to inflammatory disorders of the colon, TGF-signalling is disrupted in the mucosa of patients with IBD via the upregulation of Smad7, suggesting that strategies to reduce Smad7 levels might have therapeutic value. Subsequently it was shown that inhibition of Smad7 using antisense Smad7 oligonucleotides enhanced Smad3 phosphorylation in IBD lamina propria mononuclear cells and, also, in mucosal explants from patients with Crohn's disease [181] . Additionally, antisense Smad7 oligonucleotides have been shown to reduce inflammation in experimental mouse models of colitis, an effect which appears to be associated with the TGF--induced down-regulation of inflammatory cytokines [181, 182] . The recent patenting of Smad7 antisense oligonuceotides offers hope that antiSmad7 therapies for IBD might soon reach the clinic.
SUMMARY
In summary, TGF-1 is an important multi-functional cytokine in both normal colorectal tissue homeostasis and in tumorigenesis. Extensive literature on the complexities of its pleiotropic, contextdependent signalling, and the fact that TGF-1 signalling pathway is a common target for genetic alteration in colorectal carcinogenesis, points towards a critical role for deregulation of the TGF-1 signalling in IBD and has important implications for the progression of the IBD towards colorectal cancer. The TGF-1 cytokine has a plethora of functions according to tissue and cellular context, and in the normal colonic epithelium is involved in regulating tissue homeostasis [5, 6] . The tumour suppressive function of TGF-1 poses a barrier to transformation that tumour cells must overcome in order to allow tumour progression. Paradoxically, TGF-1 may also act as a tumour promoter in the later stages of malignant disease, and despite the fact that the contribution of potentially prooncogenic TGF-1 signalling in colorectal tumorigenesis is not well understood, inhibition of the TGF-signalling pathway in colorectal carcinogenesis may prove effective in the clinic. However, due to its potential dual roles, the TGF-1 signalling pathway represents a unique challenge when it comes to possible therapeutic intervention and further studies are needed to fully elucidate the role of TGF-1 in colorectal cancer. However, this should not prevent the activation of TGF-signalling within the context of colorectal adenoma development being considered in a chemo/therapeutic setting, Further, in a chemoprevention setting, the identification of BAG-1 as a novel regulator of TGF-1 expression in colorectal tumour cells (see above, Skeen et al, manuscript submitted) suggest that it may be possible to increase the tumour suppressive activities of TGF-1, restraining tumour growth at the adenoma stage. Bag-1 inhibitors, both pharmacological and peptide based, have been developed in Southampton [183, 184] and it will be of interest to investigate the efficacy of such reagents in reinstating suppressive TGF-signalling in adenoma derived epithelial cells. For patients at increased risk of developing colorectal cancer (including those with both chronic IBD and families with predisposing genetic factors), increasing the well established tumour suppressive activities of TGF-1 represents an exciting possibility in the search for novel therapeutics to prevent colorectal cancer.
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